Diabetes in Saudi Arabia: Prevention, Treatment, and Healthy Living in the Gulf

2. Prevalence & Major Risk Factors in Saudi Arabia and the Gulf

Authoritative sources indicate that Saudi Arabia has among the highest adult diabetes prevalence rates in the Middle East. The International Diabetes Federation (IDF) Diabetes Atlas (11th edition) and recent national surveys report adult prevalence estimates in the high twenties percent range depending on the methodology and year—placing Saudi Arabia near the top of Gulf countries in terms of population prevalence. National health reports and registries corroborate a substantial disease burden that has important clinical and economic implications.

Key drivers in the Kingdom and the wider Gulf Cooperation Council (GCC) include high levels of overweight and obesity, declining physical activity, increased consumption of energy-dense processed foods and sugar-sweetened beverages, urbanized lifestyles, and genetic predisposition. Other contributors are maternal factors (gestational diabetes and excess gestational weight gain) that increase the offspring's lifetime risk, and a demographic transition that shifts disease burden to younger ages in some populations.

Comparative regional snapshot (IDF & regional sources):

Bottom line: high prevalence in Saudi Arabia and neighboring Gulf states is driven by modifiable lifestyle factors interacting with genetic and perinatal risks, requiring multisectoral prevention strategies.

3. Types of Diabetes and How It Is Diagnosed

Diabetes is categorized clinically as: type 1 diabetes (autoimmune β-cell loss), type 2 diabetes (insulin resistance with progressive β-cell dysfunction), gestational diabetes (diagnosed during pregnancy), and less common secondary forms (e.g., monogenic diabetes, drug-induced). Differentiation relies on clinical presentation, age at onset, BMI, autoantibody testing when indicated, and the pace of insulin requirement.

Diagnostic criteria used by international authorities (ADA, WHO) include: fasting plasma glucose ≥126 mg/dL (7.0 mmol/L), HbA1c ≥6.5% (48 mmol/mol), random plasma glucose ≥200 mg/dL (11.1 mmol/L) with symptoms, or 2-hour plasma glucose ≥200 mg/dL after a 75 g oral glucose tolerance test. Special situations (hemoglobinopathies, pregnancy, recent transfusion) may limit HbA1c utility and require glucose-based testing.

Practically, laboratory confirmation is recommended (repeat testing on a separate day unless unequivocal hyperglycaemia with symptoms), and patients with prediabetes (impaired fasting glucose or impaired glucose tolerance) should be offered intensive lifestyle intervention to reduce progression risk.

4. Symptoms and Potential Complications

Common presenting symptoms include polyuria, polydipsia, unexplained weight loss, fatigue and poor concentration. However, many people with type 2 diabetes are asymptomatic for years and present only when complications develop. Chronic complications are classically divided into microvascular (retinopathy, nephropathy, neuropathy) and macrovascular (coronary artery disease, stroke, peripheral arterial disease).

Saudi registry data show significant rates of diabetic nephropathy, retinopathy and foot complications with measurable impacts on morbidity and healthcare utilization. Risk factors for complications include longer diabetes duration, poor glycaemic control (higher A1c), hypertension, dyslipidaemia and smoking. Regular surveillance—annual retinal screening, urinary albumin assessment and eGFR, foot exams—reduces the likelihood of sight loss, dialysis and limb loss.

5. Prevention & Lifestyle: diet, exercise, weight management

Type 2 diabetes prevention is effective. Randomized trials such as the Diabetes Prevention Program (DPP) showed lifestyle intervention targeting 5–7% weight loss and ≥150 minutes/week of moderate physical activity reduced diabetes incidence by ~50% in high-risk adults. Community-adapted lifestyle programs are therefore a cornerstone of national prevention strategies.

Dietary advice supported by evidence emphasizes increasing whole grains, legumes, vegetables, fruits and dietary fiber, reducing sugar-sweetened beverages and processed foods, and managing portion size. Meta-analyses link higher dietary fiber intake to lower incident type 2 diabetes risk. Physical activity recommendation includes aerobic and resistance training to improve insulin sensitivity and cardiorespiratory fitness.

Integrative tools: a structured program such as the "Feel Great" system that emphasizes increased fiber intake can align with guideline goals. Yerba mate (the botanicals in products like Unimate) has shown modest beneficial effects on glycaemic markers in small trials and meta-analyses; thus, it may be considered as an adjunct to lifestyle change for appetite control or metabolic support, but not as a substitute for established interventions. Clinicians should counsel patients on realistic expectations and potential interactions (e.g., caffeine sensitivity).

6. Treatment & Daily Management: medications, insulin, monitoring, Ramadan considerations

Treatment is individualized. For type 2 diabetes, metformin is commonly first-line (unless contraindicated). Second-line choices are informed by comorbidities: SGLT2 inhibitors and GLP‑1 receptor agonists provide cardiovascular and renal benefits in selected patients; DPP‑4 inhibitors and other agents remain options based on patient needs. Insulin is required for many patients with advanced disease or marked hyperglycaemia. For type 1 diabetes, insulin therapy is essential.

Self-monitoring of blood glucose or continuous glucose monitoring (CGM) can guide therapy, prevent hypoglycaemia and optimize outcomes in many patients. Glycaemic targets (A1c) should be individualized: tighter targets for younger, healthier patients and more relaxed targets for older patients with comorbidities or high hypoglycaemia risk.

Ramadan: many Muslim patients choose to fast. The IDF-DAR practical guidelines recommend pre-Ramadan risk assessment, individualized medication adjustment (timing and doses), and patient education on self-monitoring and when to break the fast to avoid hypo- or hyperglycaemic emergencies. Implementation of these guidelines in Saudi clinical practice reduces fasting-related complications.

7. Healthcare Resources, National Programs and a Practical Action Plan

Saudi Arabia hosts national registries (SNDR), primary care networks and Ministry of Health initiatives aligned with Vision 2030 that aim to strengthen NCD prevention and chronic disease management. Registries and electronic records support surveillance, quality improvement and resource planning. Local clinical guidelines and training programs help disseminate evidence-based care across the health system.

Practical 3-month action plan for readers:

• Weeks 1–2: baseline check (A1c or fasting glucose), blood pressure, lipid panel, weight and waist circumference; assess risk factors and medication review.
• Weeks 3–6: adopt a structured lifestyle plan—aim for +10–15 g/day fiber increase, prioritize whole foods, and start 30 min brisk walking most days; consider enrolling in a prevention program or diabetes education class.
• Months 2–3: re-evaluate with clinician for early feedback (repeat glucose as appropriate), adjust medications if needed, and refer to dietitian/diabetes educator for tailored support.

On complementary products: if considering products such as a structured fiber program or yerba mate (e.g., Unimate) as part of a "Feel Great" style system, discuss with your clinician—especially if you take glucose-lowering, anticoagulant or cardiovascular medications. Evidence for yerba mate suggests modest metabolic benefits in some trials but remains limited; thus, it should be an adjunct, not a replacement, for evidence-based therapy.

Final message: diabetes in Saudi Arabia is a major but addressable public-health problem. Combining population-level prevention, accessible primary care, patient education, evidence-based pharmacotherapy, and sustainable lifestyle interventions (including increased fiber intake) can substantially reduce the individual and societal burden of disease.